Cargando…

Type I interferon rapidly restricts infectious hepatitis C virus particle genesis

Interferon-alpha (IFNα) has been used to treat chronic hepatitis C virus (HCV) infection for over 20 years with varying efficacy, depending on the infecting viral genotype. The mechanism of action of IFNα is not fully understood, but is thought to target multiple stages of the HCV lifecycle, inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meredith, Luke W, Farquhar, Michelle J, Tarr, Alexander W, McKeating, Jane A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Viral Hepatitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265257/ https://www.ncbi.nlm.nih.gov/pubmed/25066844 http://dx.doi.org/10.1002/hep.27333

Ejemplares similares

Activated Macrophages Promote Hepatitis C Virus Entry in a Tumor Necrosis Factor-Dependent Manner
por: Fletcher, Nicola F, et al.
Publicado: (2014)

IFITM1 is a tight junction protein that inhibits hepatitis C virus entry,
por: Wilkins, Courtney, et al.
Publicado: (2013)

Paracrine Signals From Liver Sinusoidal Endothelium Regulate Hepatitis C Virus Replication
por: Rowe, Ian A, et al.
Publicado: (2014)

Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles
por: Oliveira, Catarina, et al.
Publicado: (2017)

Treatment induced clearance of hepatitis E viruses by interferon‐lambda in liver‐humanized mice
por: Sari, Gulce, et al.
Publicado: (2021)

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients
por: Chayama, Kazuaki, et al.
Publicado: (2015)

Predicting hepatitis B e Antigen seroconversion after pregnancy—The SydPregScore
por: Thilakanathan, Cynthuja, et al.
Publicado: (2022)

Global Distribution and Prevalence of Hepatitis C Virus Genotypes
por: Messina, Jane P, et al.
Publicado: (2015)

Hepatitis E virus and fulminant hepatitis–a virus or host-specific pathology?
por: Smith, Donald B, et al.
Publicado: (2015)

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)
por: Lawitz, Eric, et al.
Publicado: (2016)

Chronic Hepatitis E is associated with cholangitis
por: Beer, Andrea, et al.
Publicado: (2019)

microRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C
por: Van Keuren‐Jensen, Kendall R., et al.
Publicado: (2015)

Chronic hepatitis C viral infection subverts vaccine‐induced T‐cell immunity in humans
por: Kelly, Christabel, et al.
Publicado: (2016)

Characterization of the Specificity, Functionality, and Durability of Host T‐Cell Responses Against the Full‐Length Hepatitis E Virus
por: Brown, Anthony, et al.
Publicado: (2016)

Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection
por: Robinson, Mark W., et al.
Publicado: (2015)

Branched-chain amino acids reduce hepatic iron accumulation and oxidative stress in hepatitis C virus polyprotein-expressing mice
por: Korenaga, Masaaki, et al.
Publicado: (2015)

Over time evaluation of glycaemic control in direct‐acting antiviral‐treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis
por: Cacciola, Irene, et al.
Publicado: (2021)

Expression of Paramyxovirus V Proteins Promotes Replication and Spread of Hepatitis C Virus in Cultures of Primary Human Fetal Liver Cells
por: Andrus, Linda, et al.
Publicado: (2011)

Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan
por: Chen, Chi‐Yi, et al.
Publicado: (2021)

Spatial epidemiology of hepatitis C virus infection in Egypt: Analyses and implications
por: Cuadros, Diego F, et al.
Publicado: (2014)

Structure-Guided Design Affirms Inhibitors of Hepatitis C Virus p7 as a Viable Class of Antivirals Targeting Virion Release
por: Foster, Toshana L, et al.
Publicado: (2014)

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study
por: Kwo, Paul, et al.
Publicado: (2016)

Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States
por: Razavi, Homie, et al.
Publicado: (2013)

Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt
por: Benova, Lenka, et al.
Publicado: (2015)

Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa?
por: Desalegn, Hailemichael, et al.
Publicado: (2017)

Flunarizine prevents hepatitis C virus membrane fusion in a genotype‐dependent manner by targeting the potential fusion peptide within E1
por: Perin, Paula M., et al.
Publicado: (2015)

Estimating the Net Contribution of Interleukin-28B Variation to Spontaneous Hepatitis C Virus Clearance
por: di Iulio, Julia, et al.
Publicado: (2011)

DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection
por: Burza, Maria Antonella, et al.
Publicado: (2015)

Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C
por: Tsochatzis, Emmanuel A, et al.
Publicado: (2014)

The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment
por: Kandeel, Amr, et al.
Publicado: (2016)

Effect of Immune Pressure on Hepatitis C Virus Evolution: Insights From a Single-Source Outbreak
por: Merani, Shahzma, et al.
Publicado: (2011)

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus
por: van de Ven, Nikolien, et al.
Publicado: (2015)

Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection
por: Lattimore, Sam, et al.
Publicado: (2014)

Expression of scavenger receptor‐AI promotes alternative activation of murine macrophages to limit hepatic inflammation and fibrosis
por: Labonte, Adam C., et al.
Publicado: (2016)

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
por: Poordad, Fred, et al.
Publicado: (2016)

Transcriptome Sequencing, Microarray, and Proteomic Analyses Reveal Cellular and Metabolic Impact of Hepatitis C Virus Infection In Vitro
por: Woodhouse, Stephen D, et al.
Publicado: (2010)

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load
por: Gordon, Stuart C, et al.
Publicado: (2013)

Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine‐induced neutralizing activity
por: Kachko, Alla, et al.
Publicado: (2015)

Next-Generation Sequencing Sheds Light on the Natural History of Hepatitis C Infection in Patients Who Fail Treatment
por: Abdelrahman, Tamer, et al.
Publicado: (2015)

17,β‐estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle
por: Magri, Andrea, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0uakroq1ago22ntkju19q694rb